Novavax Inc. (Nasdaq: NVAX) will begin a Phase 1 Ebola vaccine clinical trial in December. Shares of the biopharmaceutical climbed 67 cents to close at $5.80.
Novavax to begin Ebola vaccine trials
October 27, 2014 at 17:34 PM EDT
Novavax to begin Ebola vaccine trialsOctober 27, 2014 at 17:34 PM EDT
Novavax Inc. (Nasdaq: NVAX) will begin a Phase 1 Ebola vaccine clinical trial in December. Shares of the biopharmaceutical climbed 67 cents to close at $5.80.
Related Stocks:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|